Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

BACKGROUND: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and immunogenicity of this new vaccine in West African volunteers. METHODS AND...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Brookes, R, Hill, A, Owiafe, P, Ibanga, H, Jeffries, D, Donkor, SA, Fletcher, H, Hammond, A, Lienhardt, C, Adegbola, R, McShane, H
Formato:	Journal article
Idioma:	English
Publicado em:	Public Library of Science 2008

Registros relacionados

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
por: Roger H Brookes, et al.
Publicado em: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
por: Roger H. Brookes, et al.
Publicado em: (2011-01-01)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
por: Ibanga, H, et al.
Publicado em: (2006)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
por: Owiafe, P, et al.
Publicado em: (2012)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
por: Ota, M, et al.
Publicado em: (2011)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
por: Ota, M, et al.
Publicado em: (2011)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, A, et al.
Publicado em: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
por: Pathan, A, et al.
Publicado em: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
por: Meyer, J, et al.
Publicado em: (2013)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
por: Mcshane, H, et al.
Publicado em: (2005)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
por: Whelan, K, et al.
Publicado em: (2009)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
por: Meyer, J, et al.
Publicado em: (2013)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
por: Rowland, R, et al.
Publicado em: (2012)

The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.
por: Ota, M, et al.
Publicado em: (2007)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
por: Harris, S, et al.
Publicado em: (2011)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Publicado em: (2011-01-01)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
por: White, A, et al.
Publicado em: (2013)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, A, et al.
Publicado em: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
por: Hawkridge, T, et al.
Publicado em: (2008)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
por: Betts, G, et al.
Publicado em: (2012)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
por: Kathryn T. Whelan, et al.
Publicado em: (2011-01-01)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
por: Sander, C, et al.
Publicado em: (2009)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
por: Rowland, R, et al.
Publicado em: (2013)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
por: Tameris, M, et al.
Publicado em: (2014)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
por: Thomas, Z, et al.
Publicado em: (2014)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
por: Minhinnick, A, et al.
Publicado em: (2016)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
por: Odutola, A, et al.
Publicado em: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
por: Odutola, A, et al.
Publicado em: (2012)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
por: Fletcher, H, et al.
Publicado em: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, A, et al.
Publicado em: (2017)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
por: Griffiths, K, et al.
Publicado em: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
por: Griffiths, K, et al.
Publicado em: (2011)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
por: Gareth Betts, et al.
Publicado em: (2012-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
por: Harris, S, et al.
Publicado em: (2013)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
por: Riste, M, et al.
Publicado em: (2021)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
por: Tameris, M, et al.
Publicado em: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
por: Satti, I, et al.
Publicado em: (2014)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
por: Wilkie, M, et al.
Publicado em: (2019)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
por: Dieye, T, et al.
Publicado em: (2013)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
por: Mcshane, H
Publicado em: (2008)